IMVT vs JBTM Comparison

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

JBT Marel Corp operates through two reportable segments: Protein Solutions and Prepared Food and Beverage Solutions. The Protein Solutions segment includes businesses that provide solutions for the initial stage processing and harvesting of animal proteins, mainly focusing on poultry, pork, fish, and beef. The Prepared Food and Beverage Solutions segment includes businesses that offer solutions predominantly for downstream value-added preparation, preservation, and packaging of foods and beverages into ready-to-eat or drink products. This segment will also include capabilities for pet food, dairy, bakery, pharmaceutical, nutraceutical, and warehouse automation end markets. The majority of its revenue is generated from the Prepared Food and Beverage Solutions segment.